Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is down 12% in a month after announcing a research collaboration expansion with Columbia University.
This research partnership focuses on the study of immune response to COVID-19 in healthy subjects that are asymptomatic or have recovered from the virus. Equally, it will study in vitro antibody and T cell responses to the COVID-19 causing virus, SARS-CoV-2.Most importantly, the research seeks to fill vital gaps in detailed immune responses to the virus and offer a basis for customizing therapeutics and vaccines to the right individuals through precision medicine.
The two principal study investigators for the collaboration include Sergei Rudchenko, Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, and Associate Research Scientist Ilya Trakht. Trakht is studying antibody and T Cell responses in various ways, such as stimulating T cells at the cellular level in vitro with Cov-2 antigens. So, with this research collaboration, TNXP is a biotech stock worth watching in the coming months.
Market Reaction:
On Thursday, TNXP stock went up 4% at $0.6260 with more than 11.14 million shares, compared to its average volume of 11.82 million shares. The stock has moved within a range of $0.5950 – 0.6320 after opening the trade at $0.6087.
